Research programme: bipolar depression therapeutics - PharmaMaxAlternative Names: CNS 400; CNS 401; CNS 402; CNS 403; CNS 404
Latest Information Update: 22 Jan 2016
At a glance
- Originator PharmaMax
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bipolar depression
Most Recent Events
- 22 Jan 2016 Preclinical trials in Bipolar depression in China (unspecified route)